Which reactions are listed most often in FDA adverse event reports for semaglutide and tirzepatide?

What side effects are most often reported to the FDA for semaglutide and tirzepatide?

In openFDA’s copy of FDA’s adverse event reports, checked Nov 15, 2026, the reaction terms listed most often are nausea (15,624), vomiting (10,416), off label use (9,566) for semaglutide, out of 111,278 reports, and incorrect dose administered (32,160), nausea (19,760), injection site pain (14,622) for tirzepatide, out of 181,257. These are terms reporters used, not confirmed side effects, and the counts show how often each was reported, not how often it happens.

Some of the most listed terms, such as “Off label use”, “Incorrect dose administered” and “Extra dose administered”, describe how a drug was used rather than a reaction in the body. FDA-approved labeling, not report counts, is where side effect rates are stated. Nothing here is medical advice.

FAERS reports are sent to FDA by drug makers, health professionals and the public. FDA does not verify them, a report does not show that the drug caused the event, and the same event can be reported more than once. Counts reflect how often events were reported, not how often they happen or how risky a drug is. Nothing here is medical advice. Report an error or add a company response.

Semaglutide: top 25 reaction terms

Nausea15,62414.0%
Vomiting10,4169.4%
Off label use9,5668.6%
Diarrhoea8,8047.9%
Constipation6,4815.8%
Decreased appetite6,1055.5%
Weight decreased5,5185.0%
Fatigue4,7984.3%
Impaired gastric emptying4,5494.1%
Headache4,4794.0%
Weight increased4,4794.0%
Product use in unapproved indication4,1963.8%
Abdominal pain upper4,1063.7%
Dizziness3,8903.5%
Blood glucose increased3,7253.3%
Wrong technique in product usage process3,6433.3%
Inappropriate schedule of product administration3,4673.1%
Drug ineffective3,4323.1%
Abdominal pain3,3093.0%
Malaise2,8002.5%
Dehydration2,7692.5%
Illness2,7002.4%
Asthenia2,6852.4%
Pain2,4122.2%
Dyspepsia2,3182.1%

Tirzepatide: top 25 reaction terms

Incorrect dose administered32,16017.7%
Nausea19,76010.9%
Injection site pain14,6228.1%
Diarrhoea11,3326.3%
Extra dose administered10,2885.7%
Off label use10,0425.5%
Vomiting9,4225.2%
Drug ineffective8,3014.6%
Constipation7,6304.2%
Fatigue5,7113.2%
Injection site erythema5,6253.1%
Injection site haemorrhage5,5403.1%
Product dose omission issue5,4183.0%
Accidental underdose4,6102.5%
Abdominal pain upper4,2122.3%
Weight increased4,0422.2%
Headache4,0092.2%
Injection site bruising3,9422.2%
Illness3,7322.1%
Dizziness3,6062.0%
Decreased appetite3,4731.9%
Injection site pruritus3,2611.8%
Eructation3,2171.8%
Blood glucose increased3,1811.8%
Alopecia3,0681.7%

A report can list several terms, so shares add up to more than 100%. A report is counted for a drug when any drug entry in it names the drug, whatever role the reporter gave it.

Common questions

Are these the side effects of semaglutide and tirzepatide?

Not as such. They are the terms most often written on reports sent to FDA. A report does not show that the drug caused the event, and how often something is reported depends on how many people use the drug and who reports.

Why is “Incorrect dose administered” so common for tirzepatide?

The report data shows the term but not why it was chosen; openFDA does not publish the narratives that would explain it.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.